Cefprozil is a second generation cephalosporin antibiotic and is a generic version of the brand Cefzil marketed by Bristol Myers Squibb of USA. Cefprozil is widely used in upper; lower respiratory tract infections, skin & soft tissue infections. This is the fourth cephalosporin and 38^th product of Aurobindo receiving US FDA approval. Cefprozil enjoys a market of over 100-mio dollars in the USA.

The company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies such as US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics.

The formulation portfolio is built on six technology platforms such as immediate release generics, SR/CR generics, orally disintegrating/mouth dissolving generics, combination products, sterile/lyophilized generics and liquids/dry syrups.

Aurobindo has filed over 100 DMFs and 75 ANDAs for the USA market alone in addition to filings in other countries. The pace of filings is matched by rapid product approvals from various markets. Till date Aurobindo has received 38 ANDA approvals (both final and tentative) from US FDA.

Aurobindo operates in over 100 countries and markets over 180 APIs and 250 formulations